Allena Pharmaceuticals, Inc. Long-term assets (Other)

Long-term assets (Other) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.


Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending March 31, 2022 was $123 Thousand (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) decreased by -28.9%
  • Annual Long-term assets (Other) for 2021 was $123 Thousand (a 0.0% decrease from previous year)
  • Annual Long-term assets (Other) for 2020 was $123 Thousand (a 0.0% decrease from previous year)
  • Annual Long-term assets (Other) for 2019 was $123 Thousand (a -50.0% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of Allena Pharmaceuticals, Inc.

Most recent Long-term assets (Other)of ALNA including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.12
2021 $0.12 $0.13 $0.17 $0.12 $0.12
2020 $0.12 $0.17 $0.12 $0.12 $0.12
2019 $0.12 $0.12 $0.12 $0.39 $0.12
2018 $0.25 $0.19 $0.1 $0.1 $0.25
2017 $0.09 $0.09 $0.09
2016 $0.04
2015 $0.04 $0.05

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.